DISCUSSION
NSCLC, pneumonitis, emphysema, lung cancer, pulmonary inflammation, interstitial lung disease, pulmonary disease, skin toxicity
PNEUMONITIS, STILL, EMPHYSEMA, LUNG CANCER, PULMONARY INFLAMMATION, NSCLC, INTERSTITIAL LUNG DISEASE, PULMONARY DISEASE, SKIN TOXICITY
This retrospective study analyzed 1476 advanced NSCLC patients receiving immunotherapy, ultimately including 752 patients based on stringent inclusion criteria. In the total population, 60 patients were diagnosed with CIP, and the incidence of all‐grade CIP was 8.0% (60/752), grade 1–2 pneumonitis was 4.7%, and grade 3–4 pneumonitis was 3.3%. The study identified five variables significantly associated with the occurrence of CIP by multivariate logistic analysis, which included age (>61 years), ECOG PS score of 2, higher baseline WBC (>7.1 × 10Immunotherapy has innovatively widened the scope of lung cancer therapy and has become one of the standard treatments for advanced NSCLC in recent years.As the number of older individuals receiving ICI treatment continues to rise, it becomes increasingly important to understand the potential risk of irAEs for this specific subgroup. A retrospective real‐world study indicated that the elderly population (≥70 years) who received anti‐PD‐1/PD‐L1 therapy appears to be more susceptible to the development of immune‐related skin toxicity (35.0% vs. 11.3%, Previous study indicated that prior radiotherapy history is associated with CIP for lung cancer patients receiving ICIs treatment.The biological mechanism of CIP is not fully understood yet. Several studies have demonstrated that amplified pulmonary inflammation response may account for the occurrence of CIP.In addition to the risk factors described above, pre‐existing interstitial lung disease and emphysema may also be associated with CIP. Still, there is insufficient evidence to confirm the association between these suspected factors and CIP. In a retrospective study of 54 patients with CIP, the researchers did not find a correlation between baseline pulmonary disease and CIP.The main limitation of our research is that this study is a single‐center retrospective study, which could result in selection bias. A broader treatment population must be examined to confirm our findings. Furthermore, only internal and external validation of our institution's data was conducted in our study. Additional subcenters are required to validate our findings externally. In the future, we aim to conduct a multicenter prospective study to confirm our results.